Martee Hensley
MSKCC · NRG Oncology · Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Martee Hensley as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:35 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02378142 · Pazopanib for Treating Uterine LeiomyosarcomaGynecologic Oncology Group · withdrawn · Uterine Leiomyosarcoma · study chair
- Ph3NCT01012297 · Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine LeiomyosarcomaNational Cancer Institute (NCI) · terminated · Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma · principal investigator
- N/ANCT00614835 · Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the UterusMemorial Sloan Kettering Cancer Center · completed · Uterine Leiomyosarcoma, Uterine Cancer · principal investigator
- Ph2NCT00378911 · Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the UterusNational Cancer Institute (NCI) · completed · Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma · principal investigator
- Ph2NCT00334893 · Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerNational Cancer Institute (NCI) · completed · Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer · principal investigator
- Ph2NCT00031629 · Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the UterusGynecologic Oncology Group · completed · Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Gynecologic Oncology GroupU10CA027469 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI Philip J. DiSaia · fiscal years 2012 to 2013
- Cancer Center AdministrationP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALEX MACDONALD · fiscal years 2011 to 2026Named on NCT00334893
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:35 UTC. The ranking covers the 200 most relevant of 78 PubMed records, and a shared surname and initials can bring in a namesake. All 78 on PubMed
- Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.N Engl J Med · 2003955 citationsRCR 17.4
- 660 citationsRCR 23.6
- 588 citationsRCR 14.2
- Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.J Clin Oncol · 2002509 citationsRCR 11.9
- 450 citationsRCR 11.6
- 375 citationsRCR 15.2
- A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.Clin Cancer Res · 2002366 citationsRCR 6.6
- 264 citationsRCR 9.1
- Effects of dexamethasone in primary supratentorial intracerebral hemorrhage.N Engl J Med · 1987264 citationsRCR 9.4
- Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Gynecol Oncol · 2008258 citationsRCR 6.8